DDInter521 DDInter1376
Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dexmethylphenidate {u} (Compound) resembles {v} (Compound) Cyclopentolate
Dexmethylphenidate {u} (Compound) resembles {v} (Compound) Hyoscyamine
Dexmethylphenidate {u} (Compound) binds {v} (Gene) SLC6A2
Dexmethylphenidate {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Dexmethylphenidate {u} (Compound) causes {v} (Side Effect) Muscle twitching
Dexmethylphenidate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Dexmethylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Dexmethylphenidate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ioflupane I-123
Dexmethylphenidate {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Dexmethylphenidate {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Dexmethylphenidate (Compound) resembles Cyclopentolate (Compound)
Dexmethylphenidate (Compound) resembles Hyoscyamine (Compound)
Dexmethylphenidate (Compound) binds SLC6A2 (Gene)
Dexmethylphenidate (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Dexmethylphenidate (Compound) causes Muscle twitching (Side Effect)
Dexmethylphenidate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Dexmethylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Dexmethylphenidate may lead to a major life threatening interaction when taken with Iohexol
Dexmethylphenidate may lead to a major life threatening interaction when taken with Methylene blue